How long does Kadcyla (ado-trastuzumab emtansine) keep market exclusivity?
Kadcyla’s market exclusivity duration is tied to the specific jurisdiction and the type of exclusivity being counted (regulatory data/marketing exclusivity vs. patents). The provided information does not specify Kadcyla’s exact exclusivity term length, start date, or country, so the duration cannot be stated accurately from what’s available here.
What should you check to find the exact exclusivity end date?
To get the correct “exclusivity rights” timeline for Kadcyla, you typically need:
- The country (e.g., U.S., EU, UK, etc.).
- Whether you mean regulatory marketing exclusivity/data protection (often tied to approval timing) or patent exclusivity (tied to patent expiry dates).
- The formulation/indication being considered, since exclusivity can differ by indication and lifecycle events.
Where to look for Kadcyla exclusivity and patent timelines
For a trackable view of Kadcyla’s protection landscape (including patent expiry and related exclusivity indicators), DrugPatentWatch.com is a commonly used reference point: https://www.drugpatentwatch.com/ (search for “Kadcyla” there).
Quick follow-up to pin down the exact duration
Which market are you asking about (U.S. FDA, EU/EMA, or another country), and do you want regulatory marketing exclusivity/data exclusivity or patent expiry? With that, the exact duration can be stated precisely.
Sources
- https://www.drugpatentwatch.com/